274 related articles for article (PubMed ID: 21370592)
21. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model.
Kosterink JG; McLaughlin PM; Lub-de Hooge MN; Hendrikse HH; van Zanten J; van Garderen E; Harmsen MC; de Leij LF
J Immunol; 2007 Jul; 179(2):1362-8. PubMed ID: 17617629
[TBL] [Abstract][Full Text] [Related]
24. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.
Martowicz A; Spizzo G; Gastl G; Untergasser G
BMC Cancer; 2012 Oct; 12():501. PubMed ID: 23110550
[TBL] [Abstract][Full Text] [Related]
25. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
[TBL] [Abstract][Full Text] [Related]
26. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.
Heine M; Freund B; Nielsen P; Jung C; Reimer R; Hohenberg H; Zangemeister-Wittke U; Wester HJ; Lüers GH; Schumacher U
PLoS One; 2012; 7(5):e36258. PubMed ID: 22590529
[TBL] [Abstract][Full Text] [Related]
27. Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation.
van der Gun BTF; Wasserkort R; Monami A; Jeltsch A; Raskó T; Ślaska-Kiss K; Cortese R; Rots MG; de Leij LFMH; Ruiters MHJ; Kiss A; Weinhold E; McLaughlin PMJ
Int J Cancer; 2008 Jul; 123(2):484-489. PubMed ID: 18398839
[TBL] [Abstract][Full Text] [Related]
28. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
[TBL] [Abstract][Full Text] [Related]
29. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
30. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
[TBL] [Abstract][Full Text] [Related]
31. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
32. EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
Kawashima R; Abei M; Fukuda K; Nakamura K; Murata T; Wakayama M; Seo E; Hasegawa N; Mizuguchi H; Obata Y; Hyodo I; Hamada H; Yokoyama KK
Int J Cancer; 2011 Sep; 129(5):1244-53. PubMed ID: 21710497
[TBL] [Abstract][Full Text] [Related]
33. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
34. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
35. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Schmidt M; Rüttinger D; Sebastian M; Hanusch CA; Marschner N; Baeuerle PA; Wolf A; Göppel G; Oruzio D; Schlimok G; Steger GG; Wolf C; Eiermann W; Lang A; Schuler M
Ann Oncol; 2012 Sep; 23(9):2306-2313. PubMed ID: 22357251
[TBL] [Abstract][Full Text] [Related]
36. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
Vallera DA; Zhang B; Gleason MK; Oh S; Weiner LM; Kaufman DS; McCullar V; Miller JS; Verneris MR
Cancer Biother Radiopharm; 2013 May; 28(4):274-82. PubMed ID: 23611188
[TBL] [Abstract][Full Text] [Related]
37. EpCAM: A new therapeutic target for an old cancer antigen.
Armstrong A; Eck SL
Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
[TBL] [Abstract][Full Text] [Related]
38. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Liao MY; Lai JK; Kuo MY; Lu RM; Lin CW; Cheng PC; Liang KH; Wu HC
Oncotarget; 2015 Sep; 6(28):24947-68. PubMed ID: 26317650
[TBL] [Abstract][Full Text] [Related]
39. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
40. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
